SlideShare uma empresa Scribd logo
1 de 34
Baixar para ler offline
Lee Blum, Ph.D. Testing for Bisphenol A and other Endocrine Disruptor Chemicals
Bisphenol A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bisphenol A  ,[object Object],[object Object],Population Median (25 th  – 95 th  percentile) All 2.7 ng/mL (1.3 – 15.9) 6 – 11 years 3.7 ng/mL (1.7 – 16.0) 12 – 19 years 4.2 ng/mL (1.9 – 16.5) 20 – 59 years 2.7 ng/mL (1.2 – 15.5) 60 + years 1.9 ng/mL (0.8 – 13.3) Females 2.4 ng/mL (1.2 – 15.7) Males 3.2 ng/mL (1.4 – 16.0)
Bisphenol A NTP – The Study & The Results
Bisphenol A – It’s Everywhere
Bisphenol A - Exposures ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bisphenol A - Toxicokinetics ,[object Object],[object Object],[object Object],[object Object]
Bisphenol A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
BPA – Procedure in Urine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
BPA - Instrumentation Hewlett Packard/Agilent 5973 MSD
BPA – Collection  Concerns ,[object Object],[object Object],[object Object]
BPA – Linearity in Urine Observed Concentrations (ng/mL) Target Value Day 1 Day 2 Day 3 10.0 ng/mL 10.6 10.4 10.2 5.0  ng/mL 4.90 5.02 4.99 2.5  ng/mL 2.44 2.43 2.50 1.0  ng/mL 0.98 0.98 0.98 0.25 ng/mL 0.25 0.25 0.25
BPA – Linearity in Urine
BPA - Within Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Day 1 Mean 0.30  ±   0.015 0.44  ± 0.01 6.64  ± 0.1 %CV 5.83% 1.26% 0.82% % Accuracy 104% 87.2% 88.5% Day 2 Mean 0.25  ± 0.026 0.41  ± 0.008 6.77  ± 0.1 %CV 10.4% 1.99% 1.69% % Accuracy 101% 82% 90.3% Day 3 Mean 0.23  ± 0.015 0.44  ± 0.02 6.38  ± 0.5 %CV 6.48% 3.59% 7.24% % Accuracy 93.6% 88.0% 85.1%
BPA - Between Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Mean 0.25  ±   0.02 0.43  ± 0.02 6.6  ± 0.30 %CV 8.91% 3.87% 4.63% % Accuracy 100% 86.0% 87.9%
Urine Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.15 1.0 1.15 1.12 -2.61% 2 1.75 2.5 4.25 4.05 -4.71% 3 2.61 5.0 7.61 6.87 -9.72% 4 0.41 10.0 10.4 9.26 -11.0% 5 3.89 15.0 18.9 19.0 0.53% 6 0.31 0.25 0.56 0.54 -3.57% 7 1.78 1.0 2.78 2.69 -3.24% 8 0.47 2.5 2.97 2.81 -5.39% 9 1.30 5.0 6.30 6.07 -3.65% 10 0.16 1.0 1.16 1.04 -10.3% 11 0.24 2.5 2.74 2.62 -4.38% 12 4.82 5.0 9.82 9.06 -7.74% 13 0.90 0.25 1.15 1.08 -6.09% 14 0.57 1.0 1.57 1.50 -4.46% 15 0.57 2.5 3.07 2.92 -4.89% 16 1.78 5.0 6.78 6.63 -2.21% 17 2.70 0.25 2.95 3.01 2.03% 18 4.28 1.0 5.28 5.26 -0.38% 19 1.08 2.5 3.58 3.06 -14.5% Mean Endogenous 1.57 ± 1.46 ng/mL  Mean  Bias  -5.07  ±  4.15%
BPA – Storage Stability in Urine
BPA – Storage Stability in Urine
BPA – Storage Stability in Urine
BPA – Patient Urine Samples Samples Tested 36 Median 3.2 ng/mL Range <0.25  to >10 ng/mL
BPA – 0.25 ng/mL in Urine
BPA – Typical Urine Sample
BPA – Procedure in Blood/Serum/Plasma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
BPA – Linearity in Serum
BPA – Linearity in Blood
BPA - Within Day Precision in Serum N = 5  0.25 ng/mL 0.75 ng/mL 7.5 ng/mL Mean 0.21  ±   0.01 0.80  ± 0.06 7.61  ± 0.26 %CV 5.12% 6.94% 3.42% % Accuracy 85.6% 106% 102%
BPA – Spiked Plasma Samples   Plasma Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.22 0.25 0.47 0.47 0.00% 2 0.22 2.50 2.72 2.63 -3.31% 3 0.67 0.50 1.17 1.15 -1.71% 4 0.67 5.00 5.67 5.48 -3.35% 5 0.26 1.00 1.26 1.30 3.17% 6 0.26 10.0 10.3 10.0 -2.53% 7 0.11 0.75 0.86 0.92 6.98% 8 0.11 7.50 7.61 7.52 -1.18% 9 2.10 3.00 5.10 5.31 4.12% 10 2.10 9.00 11.1 11.3 1.62% Mean Endogenous  0.67 ± 0.83 ng/mL  Mean  Bias  0.38  ± 3.49 %
BPA – Spiked Blood Samples  Blood Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target NaF 0.08 0.25 0.33 0.36 9.09% NaF 0.08 2.50 2.58 2.86 10.8% K Oxalate 0.17 0.50 0.67 0.70 4.48% K Oxalate 0.17 5.00 5.17 6.06 17.2% Na EDTA 0.18 1.00 1.18 1.32 11.9% Na EDTA 0.18 10.0 10.2 12.2 19.4% K EDTA 0.12 0.75 0.87 0.83 -4.60% K EDTA 0.12 7.50 7.62 9.00 18.1% Na Heparin 0.22 3.00 3.22 3.30 2.48% Na Heparin 0.22 9.00 9.22 10.1 9.54% Mean Endogenous  0.15 ± 0.05 ng/mL  Mean  Bias  9.85  ±  7.54%
BPA – Storage Stability in Serum
BPA – 0.25 ng/mL in Serum
BPA – 0.75 ng/mL in Blood
Endocrine Disrupting Chemicals ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Hormone Testing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[email_address] Phone: 1-800-522-6671 Lee Blum, Ph.D.

Mais conteúdo relacionado

Semelhante a Testing for BPA and other EDCs

Ccp(2) phong qiushi -ori
Ccp(2)   phong qiushi -oriCcp(2)   phong qiushi -ori
Ccp(2) phong qiushi -oriPhong Shi
 
Application of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure ModelingApplication of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure ModelingIES / IAQM
 
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamicsNews on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamicsInternational Fluid Academy
 
Laboratory reference range values app17
Laboratory reference range values app17Laboratory reference range values app17
Laboratory reference range values app17Elsa von Licy
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]ORALFLUIDLEADTEST
 
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...Igennus Healthcare Nutrition
 
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation:  Development of a Dried Blood Spot Method for LeptinSymposium presentation:  Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for LeptinJACK MAGGIORE
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellLawrence Hwang
 
Use of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic testUse of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic testDr.hema hassan
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesPine Lake Laboratories
 
Materials And Methods Of Chemicals
Materials And Methods Of ChemicalsMaterials And Methods Of Chemicals
Materials And Methods Of ChemicalsAngela Williams
 
Drugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood PosterDrugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood PosterRick Youngblood
 
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAILM.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAILSaiful Irwan Zubairi
 
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...PerkinElmer, Inc.
 
Research presentation for the first international nursing research conferenc...
Research presentation for the first international  nursing research conferenc...Research presentation for the first international  nursing research conferenc...
Research presentation for the first international nursing research conferenc...Monina Gesmundo
 
Vasopressin Case Study
Vasopressin Case StudyVasopressin Case Study
Vasopressin Case StudyJennifer Wood
 
buchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentationbuchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentationSrota Dawn
 
Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...Robert Gellibolian, Ph.D
 

Semelhante a Testing for BPA and other EDCs (20)

Ccp(2) phong qiushi -ori
Ccp(2)   phong qiushi -oriCcp(2)   phong qiushi -ori
Ccp(2) phong qiushi -ori
 
Application of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure ModelingApplication of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure Modeling
 
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamicsNews on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
 
Laboratory reference range values app17
Laboratory reference range values app17Laboratory reference range values app17
Laboratory reference range values app17
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
 
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
 
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation:  Development of a Dried Blood Spot Method for LeptinSymposium presentation:  Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
 
Use of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic testUse of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic test
 
Thesis presentation
Thesis presentationThesis presentation
Thesis presentation
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
 
Materials And Methods Of Chemicals
Materials And Methods Of ChemicalsMaterials And Methods Of Chemicals
Materials And Methods Of Chemicals
 
Drugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood PosterDrugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood Poster
 
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAILM.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
 
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
 
Research presentation for the first international nursing research conferenc...
Research presentation for the first international  nursing research conferenc...Research presentation for the first international  nursing research conferenc...
Research presentation for the first international nursing research conferenc...
 
Vasopressin Case Study
Vasopressin Case StudyVasopressin Case Study
Vasopressin Case Study
 
buchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentationbuchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentation
 
Humanbecoming
HumanbecomingHumanbecoming
Humanbecoming
 
Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...
 

Mais de NMS Labs

Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone CasesIncreasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone CasesNMS Labs
 
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...NMS Labs
 
Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012NMS Labs
 
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...NMS Labs
 
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic CannabinoidsPharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic CannabinoidsNMS Labs
 
Designer Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for EmployersDesigner Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for EmployersNMS Labs
 
Oral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE ProgramOral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE ProgramNMS Labs
 
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid PrimerK2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid PrimerNMS Labs
 
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical AnalysisK2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical AnalysisNMS Labs
 
Salvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and AnalysisSalvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and AnalysisNMS Labs
 
New Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRENew Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRENMS Labs
 
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10NMS Labs
 
NMS Labs introduction
NMS Labs introductionNMS Labs introduction
NMS Labs introductionNMS Labs
 

Mais de NMS Labs (13)

Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone CasesIncreasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
 
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
 
Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012
 
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
 
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic CannabinoidsPharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
 
Designer Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for EmployersDesigner Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for Employers
 
Oral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE ProgramOral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE Program
 
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid PrimerK2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid Primer
 
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical AnalysisK2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
 
Salvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and AnalysisSalvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and Analysis
 
New Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRENew Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRE
 
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
 
NMS Labs introduction
NMS Labs introductionNMS Labs introduction
NMS Labs introduction
 

Último

Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 

Último (20)

Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 

Testing for BPA and other EDCs

  • 1. Lee Blum, Ph.D. Testing for Bisphenol A and other Endocrine Disruptor Chemicals
  • 2.
  • 3.
  • 4. Bisphenol A NTP – The Study & The Results
  • 5. Bisphenol A – It’s Everywhere
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. BPA - Instrumentation Hewlett Packard/Agilent 5973 MSD
  • 11.
  • 12. BPA – Linearity in Urine Observed Concentrations (ng/mL) Target Value Day 1 Day 2 Day 3 10.0 ng/mL 10.6 10.4 10.2 5.0 ng/mL 4.90 5.02 4.99 2.5 ng/mL 2.44 2.43 2.50 1.0 ng/mL 0.98 0.98 0.98 0.25 ng/mL 0.25 0.25 0.25
  • 13. BPA – Linearity in Urine
  • 14. BPA - Within Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Day 1 Mean 0.30 ± 0.015 0.44 ± 0.01 6.64 ± 0.1 %CV 5.83% 1.26% 0.82% % Accuracy 104% 87.2% 88.5% Day 2 Mean 0.25 ± 0.026 0.41 ± 0.008 6.77 ± 0.1 %CV 10.4% 1.99% 1.69% % Accuracy 101% 82% 90.3% Day 3 Mean 0.23 ± 0.015 0.44 ± 0.02 6.38 ± 0.5 %CV 6.48% 3.59% 7.24% % Accuracy 93.6% 88.0% 85.1%
  • 15. BPA - Between Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Mean 0.25 ± 0.02 0.43 ± 0.02 6.6 ± 0.30 %CV 8.91% 3.87% 4.63% % Accuracy 100% 86.0% 87.9%
  • 16. Urine Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.15 1.0 1.15 1.12 -2.61% 2 1.75 2.5 4.25 4.05 -4.71% 3 2.61 5.0 7.61 6.87 -9.72% 4 0.41 10.0 10.4 9.26 -11.0% 5 3.89 15.0 18.9 19.0 0.53% 6 0.31 0.25 0.56 0.54 -3.57% 7 1.78 1.0 2.78 2.69 -3.24% 8 0.47 2.5 2.97 2.81 -5.39% 9 1.30 5.0 6.30 6.07 -3.65% 10 0.16 1.0 1.16 1.04 -10.3% 11 0.24 2.5 2.74 2.62 -4.38% 12 4.82 5.0 9.82 9.06 -7.74% 13 0.90 0.25 1.15 1.08 -6.09% 14 0.57 1.0 1.57 1.50 -4.46% 15 0.57 2.5 3.07 2.92 -4.89% 16 1.78 5.0 6.78 6.63 -2.21% 17 2.70 0.25 2.95 3.01 2.03% 18 4.28 1.0 5.28 5.26 -0.38% 19 1.08 2.5 3.58 3.06 -14.5% Mean Endogenous 1.57 ± 1.46 ng/mL Mean Bias -5.07 ± 4.15%
  • 17. BPA – Storage Stability in Urine
  • 18. BPA – Storage Stability in Urine
  • 19. BPA – Storage Stability in Urine
  • 20. BPA – Patient Urine Samples Samples Tested 36 Median 3.2 ng/mL Range <0.25 to >10 ng/mL
  • 21. BPA – 0.25 ng/mL in Urine
  • 22. BPA – Typical Urine Sample
  • 23.
  • 24. BPA – Linearity in Serum
  • 25. BPA – Linearity in Blood
  • 26. BPA - Within Day Precision in Serum N = 5 0.25 ng/mL 0.75 ng/mL 7.5 ng/mL Mean 0.21 ± 0.01 0.80 ± 0.06 7.61 ± 0.26 %CV 5.12% 6.94% 3.42% % Accuracy 85.6% 106% 102%
  • 27. BPA – Spiked Plasma Samples Plasma Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.22 0.25 0.47 0.47 0.00% 2 0.22 2.50 2.72 2.63 -3.31% 3 0.67 0.50 1.17 1.15 -1.71% 4 0.67 5.00 5.67 5.48 -3.35% 5 0.26 1.00 1.26 1.30 3.17% 6 0.26 10.0 10.3 10.0 -2.53% 7 0.11 0.75 0.86 0.92 6.98% 8 0.11 7.50 7.61 7.52 -1.18% 9 2.10 3.00 5.10 5.31 4.12% 10 2.10 9.00 11.1 11.3 1.62% Mean Endogenous 0.67 ± 0.83 ng/mL Mean Bias 0.38 ± 3.49 %
  • 28. BPA – Spiked Blood Samples Blood Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target NaF 0.08 0.25 0.33 0.36 9.09% NaF 0.08 2.50 2.58 2.86 10.8% K Oxalate 0.17 0.50 0.67 0.70 4.48% K Oxalate 0.17 5.00 5.17 6.06 17.2% Na EDTA 0.18 1.00 1.18 1.32 11.9% Na EDTA 0.18 10.0 10.2 12.2 19.4% K EDTA 0.12 0.75 0.87 0.83 -4.60% K EDTA 0.12 7.50 7.62 9.00 18.1% Na Heparin 0.22 3.00 3.22 3.30 2.48% Na Heparin 0.22 9.00 9.22 10.1 9.54% Mean Endogenous 0.15 ± 0.05 ng/mL Mean Bias 9.85 ± 7.54%
  • 29. BPA – Storage Stability in Serum
  • 30. BPA – 0.25 ng/mL in Serum
  • 31. BPA – 0.75 ng/mL in Blood
  • 32.
  • 33.